MetLife Investment Management LLC Sells 575 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

MetLife Investment Management LLC cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.1% during the 3rd quarter, Holdings Channel reports. The fund owned 53,327 shares of the biotechnology company’s stock after selling 575 shares during the period. MetLife Investment Management LLC’s holdings in Sarepta Therapeutics were worth $6,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. CIBC Asset Management Inc increased its position in Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares in the last quarter. EP Wealth Advisors LLC increased its position in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after buying an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after buying an additional 120 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 145 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on SRPT shares. Barclays decreased their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 target price for the company. Needham & Company LLC decreased their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Robert W. Baird dropped their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $133.34 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25. The firm’s 50-day moving average is $122.37 and its 200 day moving average is $131.48.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.